177 Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma.
1/5 보강
A 77-year-old man with metastatic prostate cancer presented with debilitating bone pain and rising PSA despite anti-androgen therapy.
APA
Albooyeh H, Amini H, et al. (2026). 177 Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma.. Clinical nuclear medicine, 51(2), e111-e113. https://doi.org/10.1097/RLU.0000000000005964
MLA
Albooyeh H, et al.. "177 Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma.." Clinical nuclear medicine, vol. 51, no. 2, 2026, pp. e111-e113.
PMID
40494366
Abstract
A 77-year-old man with metastatic prostate cancer presented with debilitating bone pain and rising PSA despite anti-androgen therapy. 68 Ga-PSMA PET/CT scan revealed widespread PSMA-positive bone metastases with an incidental PSMA-avid renal mass, later confirmed as renal cell carcinoma (RCC). The patient received four cycles of 177 Lu-PSMA-617, which resulted in complete pain resolution, marked improvement in bone metastases, and PSA reduction; while no change in the renal mass is noted. Despite the beneficial effects of 177 Lu-PSMA therapy in metastatic prostate cancer, its efficacy in nonprostatic malignancies is under investigation. In this case, 177 Lu-PSMA-617 did not show remarkable therapeutic efficiency in RCC.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Aged; Carcinoma, Renal Cell; Kidney Neoplasms; Lutetium; Radioisotopes; Heterocyclic Compounds, 1-Ring; Dipeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen